Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Vaccine
Shixia WangShan Lu

Abstract

An optimally effective AIDS vaccine would likely require the induction of both neutralizing antibody and cell-mediated immune responses, which has proven difficult to obtain in previous clinical trials. Here we report on the induction of human immunodeficiency virus type-1 (HIV-1)-specific immune responses in healthy adult volunteers that received the multi-gene, polyvalent, DNA prime-protein boost HIV-1 vaccine formulation, DP6-001, in a Phase I clinical trial. Robust cross-subtype HIV-1 specific T cell responses were detected in IFN-gamma ELISPOT assays. Furthermore, we detected high titer serum antibody responses that recognized a wide range of primary HIV-1 Env antigens and also neutralized pseudotyped viruses that express the primary Env antigens from multiple HIV-1 subtypes. These findings demonstrate that the DNA prime-protein boost approach is an effective immunization method to elicit both humoral and cell-mediated immune responses in humans, and that a polyvalent Env formulation could generate broad immune responses against HIV-1 viruses with diverse genetic backgrounds.

References

May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·B WangD B Weiner
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
Mar 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Douglas D RichmanChristos J Petropoulos
Mar 28, 2003·The Journal of Infectious Diseases·Marta-Louise AckersJ Steven McDougal
Sep 4, 2004·The Journal of Infectious Diseases·Jeffrey S KennedyFrancis A Ennis
Jan 11, 2005·Current HIV Research·Punnee Pitisuttithum
Feb 3, 2005·The Journal of Infectious Diseases·Neil M FlynnUNKNOWN rgp120 HIV Vaccine Study Group
Jul 13, 2006·AIDS Research and Human Retroviruses·M J MulliganUNKNOWN NIH/NIAID/DAIDS HIV Vaccine Trials Network
Oct 14, 2006·Human Vaccines·Indresh K SrivastavaSusan W Barnett
Nov 17, 2006·The Journal of Infectious Diseases·Andrew T CatanzaroUNKNOWN Vaccine Research Center 006 Study Team
Nov 17, 2006·The Journal of Infectious Diseases·Barney S GrahamUNKNOWN Vaccine Research Center 004 Study Team

❮ Previous
Next ❯

Citations

Jan 1, 2014·Vaccines·Yuxin ChenShan Lu
Feb 19, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Angela M Bodles-BrakhopRuxandra Draghia-Akli
May 15, 2009·Journal of Virology·Bette T KorberBarton F Haynes
Jan 12, 2010·Annual Review of Medicine·Dan H Barouch, Bette Korber
Oct 28, 2010·Current Opinion in HIV and AIDS·Hélène PerrinLydie Trautmann
Oct 28, 2010·Current Opinion in HIV and AIDS·Georgia D Tomaras, Barton F Haynes
Jul 19, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bernadette FerraroDavid B Weiner
Feb 8, 2013·The New England Journal of Medicine·Gary J Nabel
Jul 25, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michael VaineShixia Wang
Jan 6, 2010·Current Opinion in HIV and AIDS·Bette Korber, S Gnanakaran
Jun 8, 2013·Current Opinion in HIV and AIDS·Jean-Louis ExclerNina D Russell
Mar 3, 2010·Annual Review of Immunology·John R Mascola, David C Montefiori
Oct 15, 2009·Annual Review of Medicine·James A Hoxie
Dec 29, 2011·Current HIV/AIDS Reports·Ann J Hessell, Nancy L Haigwood
Jun 19, 2012·AIDS·Kevin O SaundersGary J Nabel
May 11, 2013·Expert Review of Vaccines·Daniel O VillarrealDavid B Weiner
May 16, 2012·Expert Opinion on Biological Therapy·Sandhya Vasan, Nelson L Michael
Aug 27, 2010·Journal of Pharmaceutical Sciences·Yuhong ZengC Russell Middaugh
Aug 18, 2010·Vaccine·Fred Zepp
Mar 20, 2010·Current Opinion in Immunology·Laura M Walker, Dennis R Burton
Oct 20, 2009·Vaccine·Shan Lu, Shixia Wang
Jun 9, 2009·Current Opinion in Immunology·Shan Lu
Mar 11, 2008·Biochemical and Biophysical Research Communications·Anthony D CristilloRanajit Pal
Feb 26, 2016·Expert Review of Vaccines·Thomas Musich, Marjorie Robert-Guroff
Jun 19, 2013·Immunological Reviews·John R Mascola, Barton F Haynes
Apr 7, 2016·Emerging Microbes & Infections·Shuying LiuShan Lu
Apr 29, 2015·American Journal of Reproductive Immunology : AJRI·Kripa N NandGursaran P Talwar
Feb 12, 2014·Human Vaccines & Immunotherapeutics·Rachel Buglione-CorbettShan Lu
May 28, 2011·International Immunopharmacology·Rajeev Nagill, Sukhbir Kaur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.